Travere Therapeutics to Report Second Quarter 2022 Financial Results
Rhea-AI Summary
Travere Therapeutics (NASDAQ: TVTX) is set to release its Q2 2022 financial results on August 4, 2022, before the U.S. market opens. A conference call will be held at 8:00 a.m. ET to discuss the results and offer a business update. For those unable to attend live, a replay will be available from 11:00 a.m. ET on August 4 until 11:00 a.m. ET on August 11, 2022. Travere Therapeutics focuses on developing therapies for rare diseases, aligning its operations with the urgent needs of patients and their families.
Positive
- None.
Negative
- None.
News Market Reaction – TVTX
In the trading session that priced this news, TVTX declined 2.49%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, July 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2022 financial results on Thursday, August 4, 2022 before the open of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 8:00 a.m. ET.
Conference Call Information
| Date: | Thursday, August 4, 2022 | |
| Time: | 8:00 a.m. ET | |
| Dial-in numbers: | +1 (888) 220-8474 (U.S.) or +1 (313) 209-6544 (International) | |
| Confirmation code: | 5371785 | |
| Live webcast: | Travere.com in the “Events & Presentations” section of the “Investors” page |
A replay of the call will be available from 11:00 a.m. ET, August 4, 2022, to 11:00 a.m. ET, August 11, 2022. The replay number is +1 (888) 203-1112 (U.S.) or +1 (719) 457-0820 (International), confirmation code 5371785.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com
Contact:
Chris Cline, CFA
Senior Vice President, Investor Relations & Corporate Communications
888-969-7879
IR@travere.com
